markets

Arian Neiron has spent 12 years building VanEck's Asia Pacific business from scratch, with plenty of lessons to unpack.

She was bullish on PME at $25 and is still adding, confident there’s plenty of upside left in the trade.

The telco giant beat profit expectations but follows other big ASX peers downwards following mixed FY25 results.

A lack of ROI and diminishing returns make it a question of when, not if.

Mid-cap stocks sit in the alpha sweet spot — with better growth than large caps, but lower risk than small ones.

Early bird offer ends this Friday.

Life360 trades at over twice the multiple of peers like Uber. CFO Russell Burke shares why and how the company plans to hit big targets.

Revenue jumps 34%, users hit 88M. Now Lauren Antonoff takes charge to steer the family safety giant higher.

Markets will climb several walls of worry, but ultimately will benefit from a strengthening earnings outlook, suggests major broker Citi.

You don't often see huge yields on asset managers that are highly rated by the market. So what's going on?

The fundie suggested the odd negative share price reaction in QBE can create opportunity for investors.

Japan has been in the news a lot lately. The US announced a trade deal with Japan last week, which essentially settles the tariff for Japanese goods exports to the US...

Trade uncertainty may be easing as the US strikes deals with partners, but import tariffs remain high in the world’s largest economy.

Soul Patts becomes the market's first dividend aristocrat, with a newly discovered 27-year streak of consecutive dividend increases.

Legendary value investor Rich Pzena shares the mindset and math behind buying great businesses when no one else wants them.

Mr Frazis plans to bring his brash style to more ASX investors with the launch of a tech stock focused ETF by October.

Rudi Filapek-Vandyck on sky high valuations, falling earnings and the AI stocks he’s got on his radar

Figma's spectacular IPO has cranked excitement around Canva's potential to go public in a US market with a wild appetite for tech stars.

Elston’s Bruce Williams discuss ResMed's results and margin momentum, and whether the stock still deserves a buy rating.

Not sure where to start this ASX FY25 reporting season? NAOS analyses keywords in earnings call transcripts to reveal the common themes.